Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on cell therapy drugs for ophthalmic diseases. Porton Advanced will provide comprehensive CDMO services to support iPSC-derived retinal pigment epithelium cell (RPEC)...
JOIN FDI WORLD DENTAL FEDERATION’S 2025 VIRTUAL SUMMIT TO ADVANCE SUSTAINABLE PRACTICES IN DENTISTRY AND REDUCE THE PROFESSION’S ENVIRONMENTAL IMPACT
GENEVA, May 22, 2025 /PRNewswire/ -- FDI World Dental Federation (FDI) is proud to announce the third edition of its Virtual Summit on Sustainability in Dentistry, taking place from 05 - 06 June 2025 from 10:00 to 11:30 AM EST / 04:00 to 05:30 PM CEST. This landmark event continues to provide a global platform for exchanging knowledge, showcasing real-world...
EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO
Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials. LONDON, May 22, 2025 /PRNewswire/ -- Comac Medical Group ("Group"), based in the UK and backed by EdgeCap Partners, announced today the acquisition of ILIFE Consulting ("ILIFE"), a specialized Contract Research Organization (CRO) headquartered in...
Waterdrop Inc. to Report First Quarter 2025 Financial Results on June 5, 2025
BEIJING, May 21, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before U.S. markets open on Thursday, June 5, 2025. Waterdrop's management team will hold a...
€2.6 million innovation challenge launches in Southeast Asia to reimagine support for new parents
LONDON, May 22, 2025 /PRNewswire/ -- Smart, public 'parent pods' located in central community spaces such as markets or parks could soon become a reality around the world as a result of the Good Start Challenge: a €2.6 million global challenge launching today with a call for innovations that improve the wellbeing of parents of young children in underserved...
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year PARIS, May 22, 2025 /PRNewswire/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center in Gifu, Japan presented the...
JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform
Global eye experts reunite in Jakarta for JECIM 2025, after five-year hiatus JEC showcases 41 years of ophthalmology leadership and innovation Launch of Matapedia marks new chapter in eye health education JAKARTA, Indonesia, May 22, 2025 /PRNewswire/ -- JEC Eye Hospitals and Clinics, Indonesia's leading eye care providerwith more than four decades of clinical excellence, hosts...
MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
HAMBURG, Germany, May 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of the Smart8 at SLAS Europe 2025, taking place...
Fourth NDA for Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation
CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) was accepted by the Center for Drug Evaluation (CDE) of the...
AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients
TAIPEI, May 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-controlled, first-in-patient clinical trial of AJ201 in adults with Spinal and Bulbar Muscular Atrophy (SBMA). Conducted across six U.S. clinical...
